Arix notes Iterum?s proposed US IPO

RNS Number : 8795M

Arix Bioscience Plc

02 May 2018

 

Arix Bioscience plc

Iterum announces confidential submission of draft registration statement for proposed initial public offering in the United States

2 May 2018 Arix Bioscience plc (LSE:ARIX) ("Arix"), a global healthcare and life science company supporting medical innovation, today notes that its Group Business Iterum Therapeutics ("Iterum") has submitted a registration statement on Form S-1 to the US Securities and Exchange Commission relating to a proposed initial public offering ("IPO") of ordinary shares in the United States. Iterum has applied to list its ordinary shares on the Nasdaq Global Select Market under the symbol "ITRM." The timing and the terms of this proposed initial public offering have not yet been determined and are subject to market conditions and other factors.

ENDS

For more information on Arix, please contact:

Arix Bioscience plc

Charlotte Parry, Investor Relations Manager

[phone]

[e-mail]

Consilium Strategic Communications

Mary-Jane Elliott, Jessica Hodgson, Ivar Milligan

[phone]

[e-mail]

About Arix Bioscience plc

Arix Bioscience plc is a global healthcare and life science company supporting medical innovation. Headquartered in London and with an office in New York, Arix Bioscience sources, finances and builds world class healthcare and life science businesses addressing medical innovation at all stages of development. Operations are supported by privileged access to breakthrough academic science and strategic relationships with leading research accelerators and global pharmaceutical companies.

Arix Bioscience plc is listed on the Main Market of the London Stock Exchange. For further information, please visit www.arixbioscience.com

About Iterum Therapeutics plc

Iterum Therapeutics plc (Iterum Therapeutics) is an Irish clinical-stage pharmaceutical company dedicated to developing differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. Iterum Therapeutics is advancing its first compound, sulopenem, a novel penem anti-infective compound with oral and IV formulations that has demonstrated potent in vitro activity against a wide variety of gram-negative, gram-positive and anaerobic bacteria resistant to other antibiotics. Iterum Therapeutics has received QIDP designations for its oral and IV formulations for the treatment of uUTI, cUTI and cIAI. Iterum Therapeutics is led by a highly experienced team and backed by a blue-chip venture capital syndicate. For more information, please visit www.iterumtx.com.

 

END

 

 

MSCLIFIAEAIFIIT